Inozyme is committed to developing novel therapies to treat rare and seriously debilitating diseases of abnormal mineralization. Our goal is to provide access to our medicines at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe that focusing on initiation and conduct of clinical trials is the safest and most effective way of achieving this goal. Information about our clinical trials is available at www.clinicaltrials.gov.
Inozyme understands that some patients with no other viable treatment options may wish to access our medicines before results of a clinical trial are available, or they may not meet the eligibility criteria for an available clinical trial. Inozyme recognizes the need for Expanded Access Programs for these patients.
Inozyme continues to assess the eligibility requirements and criteria for expanded access. At this time, an Expanded Access Program is not available. However, we are aware of a potentially high need and will re-evaluate the status of this policy on a regular basis.
If you have additional questions regarding this policy, please speak with your healthcare provider or contact: firstname.lastname@example.org.